Related Experiment Videos
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis
L D Jacobs1, D L Cookfair, R A Rudick
1Department of Neurology, Buffalo General Hospital, New York 14203, USA.
Annals of Neurology
|March 1, 1996
Summary
Interferon beta-1a significantly slowed disability progression in relapsing multiple sclerosis patients. This treatment also reduced exacerbations and brain lesion activity, offering a new therapeutic option.
Area of Science:
- Neurology
- Immunology
Background:
- Current relapsing multiple sclerosis treatments manage symptoms but do not alter disease progression.
- There is a critical need for therapies that can slow irreversible neurological disability.
Purpose of the Study:
- To evaluate the efficacy of interferon beta-1a in slowing the progressive neurological disability in relapsing multiple sclerosis.
- To assess the impact of interferon beta-1a on exacerbation frequency and magnetic resonance imaging (MRI) disease activity.
Main Methods:
- A randomized, double-blind, placebo-controlled, multicenter phase III trial involving 301 relapsing multiple sclerosis patients.
- Interferon beta-1a (6.0 million units) administered intramuscularly weekly.
- Primary outcome: time to sustained disability progression measured by the Kurtzke Expanded Disability Status Scale (EDSS).
Main Results:
- Interferon beta-1a significantly delayed sustained EDSS progression (p=0.02).
- Proportion of patients progressing by 104 weeks was 21.9% with interferon beta-1a vs. 34.9% with placebo.
- Treated patients showed fewer exacerbations (p=0.03) and reduced MRI gadolinium-enhanced lesions (p=0.02-0.05).
Conclusions:
- Interferon beta-1a demonstrated a significant beneficial impact on relapsing multiple sclerosis.
- The treatment reduced accumulation of permanent physical disability, decreased exacerbation frequency, and lowered brain MRI disease activity.
- Interferon beta-1a may alter the fundamental course of relapsing multiple sclerosis.